[go: up one dir, main page]

PE20171056A1 - Derivados de piridin-2(1h)-on quinolinona como inhibidores de isocitrato deshidrogenasa - Google Patents

Derivados de piridin-2(1h)-on quinolinona como inhibidores de isocitrato deshidrogenasa

Info

Publication number
PE20171056A1
PE20171056A1 PE2017000471A PE2017000471A PE20171056A1 PE 20171056 A1 PE20171056 A1 PE 20171056A1 PE 2017000471 A PE2017000471 A PE 2017000471A PE 2017000471 A PE2017000471 A PE 2017000471A PE 20171056 A1 PE20171056 A1 PE 20171056A1
Authority
PE
Peru
Prior art keywords
pyridin
inhibitors
oxo
methyl
quinolinone
Prior art date
Application number
PE2017000471A
Other languages
English (en)
Inventor
Susan Ashwell
Ann-Marie Campbell
Justin Andrew Caravella
R Bruce Diebold
Anna Ericsson
Gary Gustafson
David R Lancia
Jian Lin
Wei Lu
Zhongguo Wang
Original Assignee
Forma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forma Therapeutics Inc filed Critical Forma Therapeutics Inc
Publication of PE20171056A1 publication Critical patent/PE20171056A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se refiere a un derivado de piridin-2(1H)-on quinolinona de formula I, donde: W1 y W2 es CH, CF o N; W3 es CR2 o N; U es N o CR6; A es H, halogeno, entre otros; R1 es OH, CN, entre otros; R2 es H, OH, entre otros; R3 es H, alquilo C1-C6 u -OH; R4 y R5 son H, halogeno, entre otros; R6 es H, alquilo C1-C6, entre otros; R9 es H, entre otros. Son compuestos preferidos: 5-{[(6-cloro-2-oxo-1,2-dihidroquinolin-3-il)metil]amino}-1-metil-6-oxo-1,6-dihidropiridin-2-carbonitrilo;6-cloro-3-{[(1-etil-2-oxo-1,2-dihidropiridin-3-il)amino]metil}-1,2-dihidroquinolin-2-ona; entre otros. Tambien se refiere a una composicion farmaceutica. Dichos compuestos son inhibidores de proteinas de isocitrato deshidrogenasa mutante (mt-IDH) con actividad neomorfica siendo utiles en el tratamiento de trastornos de proliferacion celular y cancer
PE2017000471A 2014-09-19 2015-09-18 Derivados de piridin-2(1h)-on quinolinona como inhibidores de isocitrato deshidrogenasa PE20171056A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462053006P 2014-09-19 2014-09-19
US201562128089P 2015-03-04 2015-03-04
US201562150812P 2015-04-21 2015-04-21

Publications (1)

Publication Number Publication Date
PE20171056A1 true PE20171056A1 (es) 2017-07-21

Family

ID=54291606

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017000471A PE20171056A1 (es) 2014-09-19 2015-09-18 Derivados de piridin-2(1h)-on quinolinona como inhibidores de isocitrato deshidrogenasa

Country Status (37)

Country Link
US (8) US9834539B2 (es)
EP (4) EP4257131A3 (es)
JP (1) JP6648115B2 (es)
KR (1) KR102209667B1 (es)
CN (3) CN107001328B (es)
AU (3) AU2015317329B2 (es)
BR (1) BR112017005238B1 (es)
CA (1) CA2961817C (es)
CL (1) CL2017000658A1 (es)
CO (1) CO2017003241A2 (es)
CY (2) CY1121149T1 (es)
DK (2) DK3194376T3 (es)
EA (1) EA034336B1 (es)
EC (1) ECSP17022933A (es)
ES (3) ES2953347T3 (es)
FI (1) FI3733662T3 (es)
HR (1) HRP20200666T1 (es)
HU (2) HUE041460T2 (es)
IL (3) IL292608B2 (es)
LT (2) LT3447050T (es)
MA (2) MA53352A (es)
ME (1) ME03776B (es)
MX (2) MX385512B (es)
MY (2) MY176250A (es)
NZ (1) NZ730373A (es)
PE (1) PE20171056A1 (es)
PH (1) PH12017500517B1 (es)
PL (3) PL3447050T3 (es)
PT (3) PT3447050T (es)
RS (2) RS58184B1 (es)
SA (1) SA517381129B1 (es)
SG (1) SG11201702194SA (es)
SI (2) SI3194376T1 (es)
SM (2) SMT202000212T1 (es)
TW (1) TWI686390B (es)
WO (1) WO2016044789A1 (es)
ZA (3) ZA201702127B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6067226B2 (ja) 2009-03-13 2017-01-25 アジオス ファーマシューティカルズ， インコーポレイテッド 細胞増殖関連疾患のための方法および組成物
WO2011050210A1 (en) 2009-10-21 2011-04-28 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
SI3406609T1 (sl) 2014-02-06 2024-10-30 Nxera Pharma Uk Limited Biciklične aza spojine kot agonisti muskarinskega receptorja
ES2953347T3 (es) 2014-09-19 2023-11-10 Forma Therapeutics Inc Derivados de piridin-2(1H)-ona quinolinona como inhibidores de isocitrato deshidrogenasa mutante
WO2016044787A1 (en) 2014-09-19 2016-03-24 Forma Therapeutics, Inc. Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
JP6664385B2 (ja) 2014-09-19 2020-03-13 バイエル ファーマ アクチエンゲゼルシャフト Ｂｕｂ１阻害薬としてのベンジル置換インダゾール類
JP6648116B2 (ja) * 2014-09-19 2020-02-14 フォーマ セラピューティクス，インコーポレイテッド 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのキノリノンピリミジン組成物
WO2016044782A1 (en) 2014-09-19 2016-03-24 Forma Therapeutics, Inc. Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
JP6901394B2 (ja) 2014-12-22 2021-07-14 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 癌の処置に有用な変異型ｉｄｈ１阻害剤
US9624216B2 (en) 2015-04-21 2017-04-18 Forma Therapeutics, Inc. Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
US10294206B2 (en) 2015-04-21 2019-05-21 Forma Tm2, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
WO2018202524A1 (de) 2017-05-04 2018-11-08 Bayer Cropscience Aktiengesellschaft 2-{[2-(phenyloxymethyl)pyridin-5-yl]oxy}-ethanamin-derivate und verwandte verbindungen als schädlingsbekämpfungsmittel z.b. für den pflanzenschutz
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
WO2019222551A1 (en) 2018-05-16 2019-11-21 Forma Therapeutics, Inc. Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
US11013733B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
DK3720442T3 (da) 2018-05-16 2023-03-27 Forma Therapeutics Inc Inhibering af mutant idh-1
US11576906B2 (en) 2018-05-16 2023-02-14 Forma Therapeutics, Inc. Inhibiting mutant IDH-1
WO2020232381A1 (en) 2019-05-16 2020-11-19 Forma Therapeutics, Inc. INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1)
TW202104207A (zh) * 2019-04-17 2021-02-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
US11566013B1 (en) * 2019-11-20 2023-01-31 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH1)
CN112341389B (zh) * 2020-10-27 2022-07-29 浙江工业大学 一种含氮芳杂环取代的喹啉甲酰胺类衍生物及其应用
CN112321571B (zh) * 2020-10-27 2022-06-03 浙江工业大学 2-呋喃-喹啉-4-甲酰胺类化合物及其应用
CN115850240B (zh) * 2022-12-28 2023-09-19 北京康立生医药技术开发有限公司 一种治疗急性髓系白血病药物奥卢他西尼的合成方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99731A0 (en) 1990-10-18 1992-08-18 Merck & Co Inc Hydroxylated pyridine derivatives,their preparation and pharmaceutical compositions containing them
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
US20030105124A1 (en) 2000-04-27 2003-06-05 Susan Beth Sobolov-Jaynes Substituted benzolactam compounds
CA2488635C (en) 2002-06-12 2012-10-23 Abbott Laboratories Antagonists of melanin concentrating hormone receptor
AU2003284399A1 (en) 2002-11-14 2004-06-03 Kyowa Hakko Kogyo Co., Ltd. Plk inhibitors
RU2284325C2 (ru) 2003-12-17 2006-09-27 Общество С Ограниченной Ответственностью "Асинэкс Медхим" Производные фенил-3-аминометил-хинолона-2 в качестве ингибиторов no-синтетазы, способ их получения, биологически активные соединения и фармацевтическая композиция на их основе
EP1749827A4 (en) 2004-03-30 2010-04-21 Kyowa Hakko Kirin Co Ltd ANTITUMOR AGENTS
WO2006054912A1 (fr) 2004-11-18 2006-05-26 Obchestvo S Ogranichennoy Otvetstvennost'u 'asineks Medhim' Derives d'aryl(hetaryl)-3-aminomethylchinolone-2 utilises en tant qu'inhibiteurs de no-synthetase et de cyclo-oxygenase-2, procedes de leur fabrication et compositions pharmaceutiques sur leur base
TW200803855A (en) 2006-02-24 2008-01-16 Kalypsys Inc Quinolones useful as inducible nitric oxide synthase inhibitors
CA2657287A1 (en) * 2006-07-17 2008-01-24 Merck & Co., Inc. 1-hydroxy naphthyridine compounds as anti-hiv agents
JP2010043004A (ja) 2006-12-06 2010-02-25 Dainippon Sumitomo Pharma Co Ltd 新規２環性複素環化合物
CN101679321B (zh) 2007-04-30 2012-10-03 普罗米蒂克生物科学公司 三嗪衍生物、含所述衍生物的组合物以及所述衍生物在制备用于治疗癌症和自身免疫性疾病药物中的应用
CA2764785C (en) 2009-06-08 2015-10-27 California Capital Equity, Llc Triazine derivatives and their therapeutical applications
WO2011072174A1 (en) * 2009-12-09 2011-06-16 Agios Pharmaceuticals, Inc. Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation
US9073941B2 (en) 2010-06-28 2015-07-07 Academia Sinica Compounds and methods for treating tuberculosis infection
CN102558049B (zh) 2010-12-17 2015-02-04 中国科学院上海药物研究所 一类双香豆素类化合物及其制备方法和用途
US20120184562A1 (en) 2011-01-19 2012-07-19 Kin-Chun Luk 1,6- and 1,8-naphthyridines
US20120184548A1 (en) 2011-01-19 2012-07-19 Romyr Dominique Carboxylic acid aryl amides
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN103814020B (zh) * 2011-06-17 2017-07-14 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
TWI547493B (zh) 2011-09-27 2016-09-01 諾華公司 作為突變ｉｄｈ之抑制劑之３－嘧啶－４－基－唑啶－２－酮
CA2859985C (en) 2011-12-21 2020-11-03 The Regents Of The University Of Colorado Anti-cancer compounds targeting ral gtpases and methods of using the same
EP3984997B1 (en) * 2012-01-06 2025-07-30 Les Laboratoires Servier Therapeutically active compounds and their methods of use
KR20150127197A (ko) 2013-03-14 2015-11-16 노파르티스 아게 돌연변이 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온
US10478445B2 (en) 2013-07-03 2019-11-19 Georgetown University Boronic acid derivatives of resveratrol for activating deacetylase enzymes
CA2939026A1 (en) 2014-02-11 2015-08-20 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as midh1 inhibitors
WO2016044787A1 (en) 2014-09-19 2016-03-24 Forma Therapeutics, Inc. Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
JP6648116B2 (ja) * 2014-09-19 2020-02-14 フォーマ セラピューティクス，インコーポレイテッド 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのキノリノンピリミジン組成物
ES2953347T3 (es) * 2014-09-19 2023-11-10 Forma Therapeutics Inc Derivados de piridin-2(1H)-ona quinolinona como inhibidores de isocitrato deshidrogenasa mutante
WO2016044782A1 (en) 2014-09-19 2016-03-24 Forma Therapeutics, Inc. Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
JP6901394B2 (ja) 2014-12-22 2021-07-14 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 癌の処置に有用な変異型ｉｄｈ１阻害剤
GB2533925A (en) 2014-12-31 2016-07-13 Univ Bath Antimicrobial compounds, compositions and methods
US9624216B2 (en) 2015-04-21 2017-04-18 Forma Therapeutics, Inc. Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
US10294206B2 (en) 2015-04-21 2019-05-21 Forma Tm2, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
EP3328866B1 (en) 2015-07-27 2019-10-30 Eli Lilly and Company 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds and theit use as mutant idh1 inhibitors
AU2016393870B2 (en) 2016-02-26 2023-01-19 Celgene Corporation IDH1 inhibitors for the treatment of haematological malignancies and solid tumours
US10696665B2 (en) 2016-06-06 2020-06-30 Eli Lilly And Company Mutant IDH1 inhibitors
CA3028999A1 (en) 2016-06-22 2017-12-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thiazole derivatives useful as mutant idh1 inhibitors for treating cancer
MY197313A (en) 2016-12-16 2023-06-13 Lilly Co Eli 7-phenylethlamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors

Also Published As

Publication number Publication date
ES2790640T3 (es) 2020-10-28
JP2017528487A (ja) 2017-09-28
EP3194376B1 (en) 2018-10-24
TW201617335A (zh) 2016-05-16
US20230125739A1 (en) 2023-04-27
US20210078973A1 (en) 2021-03-18
BR112017005238B1 (pt) 2023-01-17
US20180312487A1 (en) 2018-11-01
ZA202304409B (en) 2024-08-28
US20190263778A1 (en) 2019-08-29
IL282363B (en) 2022-06-01
HUE062424T2 (hu) 2023-11-28
WO2016044789A1 (en) 2016-03-24
HUE041460T2 (hu) 2019-05-28
EP4257131A3 (en) 2024-01-10
US11498913B2 (en) 2022-11-15
IL292608B2 (en) 2024-10-01
PT3447050T (pt) 2020-09-17
MA53352A (fr) 2021-09-15
NZ758641A (en) 2023-12-22
US10889567B2 (en) 2021-01-12
PT3194376T (pt) 2019-02-04
PL3447050T3 (pl) 2020-07-27
ME03776B (me) 2021-04-20
EP3733662B1 (en) 2023-06-07
IL282363A (en) 2021-06-30
US10550098B2 (en) 2020-02-04
CY1122865T1 (el) 2021-05-05
EP3733662A1 (en) 2020-11-04
TWI686390B (zh) 2020-03-01
NZ730373A (en) 2019-11-29
RS58184B1 (sr) 2019-03-29
AU2021215141B2 (en) 2023-10-19
EA034336B1 (ru) 2020-01-29
US12275715B2 (en) 2025-04-15
CN111909130B (zh) 2023-10-31
EP3447050B1 (en) 2020-02-19
ZA201902446B (en) 2023-12-20
KR102209667B1 (ko) 2021-01-29
MA40481A (fr) 2017-07-26
PL3194376T3 (pl) 2019-05-31
ES2953347T3 (es) 2023-11-10
US20240150319A1 (en) 2024-05-09
IL251163B (en) 2021-05-31
LT3447050T (lt) 2020-05-11
US20200223822A1 (en) 2020-07-16
CN107001328A (zh) 2017-08-01
CA2961817C (en) 2024-03-12
CA2961817A1 (en) 2016-03-24
AU2021215141A1 (en) 2021-09-02
KR20170063742A (ko) 2017-06-08
DK3447050T3 (da) 2020-03-09
EP3194376A1 (en) 2017-07-26
US20170174658A1 (en) 2017-06-22
ECSP17022933A (es) 2017-08-31
SA517381129B1 (ar) 2021-04-26
US10414752B2 (en) 2019-09-17
PT3733662T (pt) 2023-08-18
ZA201702127B (en) 2019-06-26
IL251163A0 (en) 2017-04-30
HRP20200666T1 (hr) 2020-07-24
SI3447050T1 (sl) 2020-08-31
CY1121149T1 (el) 2020-05-29
SMT202000212T1 (it) 2020-05-08
FI3733662T3 (fi) 2023-08-09
SMT201900018T1 (it) 2019-02-28
CN111909130A (zh) 2020-11-10
PH12017500517B1 (en) 2022-08-03
RS60140B1 (sr) 2020-05-29
US20160083366A1 (en) 2016-03-24
CN117695280A (zh) 2024-03-15
MX2019013203A (es) 2020-01-20
AU2015317329B2 (en) 2019-10-31
AU2015317329A1 (en) 2017-04-27
AU2019283765A1 (en) 2020-01-16
MX385512B (es) 2025-03-18
DK3194376T3 (en) 2019-01-21
ES2704897T3 (es) 2019-03-20
SI3194376T1 (sl) 2019-03-29
JP6648115B2 (ja) 2020-02-14
BR112017005238A2 (pt) 2017-12-19
IL292608A (en) 2022-07-01
LT3194376T (lt) 2019-02-25
CN107001328B (zh) 2020-06-05
MY176250A (en) 2020-07-24
CO2017003241A2 (es) 2017-09-20
EP3447050A1 (en) 2019-02-27
EP4257131A2 (en) 2023-10-11
MY197533A (en) 2023-06-21
EA201790657A1 (ru) 2017-08-31
MX2017003404A (es) 2017-07-28
PL3733662T3 (pl) 2024-01-22
US9834539B2 (en) 2017-12-05
EA201790657A8 (ru) 2018-02-28
AU2019283765B2 (en) 2021-05-13
CL2017000658A1 (es) 2017-12-22
IL292608B1 (en) 2024-06-01
PH12017500517A1 (en) 2017-08-07
SG11201702194SA (en) 2017-04-27

Similar Documents

Publication Publication Date Title
PE20171056A1 (es) Derivados de piridin-2(1h)-on quinolinona como inhibidores de isocitrato deshidrogenasa
MX2017003626A (es) Derivados de piridinil quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh).
MX2017003627A (es) Composiciones de pirimidin quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh).
PE20150734A1 (es) Inhibidores de glucosilceramida sintasa
EA201591745A1 (ru) 3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантого idh
PE20160934A1 (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolisis
EA202092636A1 (ru) Способ синтеза 2-гидрокси-6-((2-(1-изопропил-1h-пиразол-5-ил)пиридин-3-ил)метокси)бензальдегида
MX2017003637A (es) Derivados de fenil quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh).
EA201400333A1 (ru) Бензонитрильные производные в качестве ингибиторов киназ
MX387984B (es) Inhibidor del egfr y preparación y aplicación del mismo.
CA2919397C (en) Aryl ethers as hif-2.alpha. inhibitors for the treatment of cancer
MX2016001037A (es) Inhibidores de factores de transcripción y usos.
EA201891917A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
EA201391236A1 (ru) Новые циклические производные азабензимидазола, используемые в качестве антидиабетических агентов
PE20170143A1 (es) Benzimidazol-2-aminas como inhibidores de midh1
PE20141283A1 (es) Nuevos derivados biciclicos de dihidroisoquinolin-1-ona
EA201592082A1 (ru) 3,4-дигидроизохинолин-2(1h)-ильные соединения
PE20160050A1 (es) Inhibidores/ antiandrogenos novedosos de cyp17
PE20170640A1 (es) Derivados de quinolizinona como inhibidores de pi3k
PE20081893A1 (es) Subtipo de amidas selectivas de diazabicicloalcanos
BR112014005864A2 (pt) compostos de beta-lactama para tratar diabetes
PE20171736A1 (es) Derivados de 3-(4'-sustituido)-bencil-eter de pregnenolona
EA201992489A2 (ru) Хинолиноновые производные пиридин-2(1h)-она как ингибиторы мутантной изоцитратдегидрогеназы
HK1242300A1 (en) Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors